DNA MOLECULES ENCODING THE MELANOCORTIN 5 RECEPTOR PROTEIN FROM RHESUS MONKEY

The present invention relates to rhesus monkey DNA molecules encoding the melanocortin-5 receptor protein, recombinant vectors comprising DNA molecules encoding rhesus MC-5R, recombinant host cells which contain a recombinant vector encoding rhesus MC-5R, the rhesus MC-5R protein encoded by the DNA molecule, and methods of identifying selective agonists and antagonists of rhesus MC-5R.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lesotho</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslav</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MR</td>
<td>Mauritania</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KP</td>
<td>Democratic People's</td>
<td>PL</td>
<td>Poland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PT</td>
<td>Portugal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>RO</td>
<td>Romania</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RU</td>
<td>Russian Federation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SD</td>
<td>Sudan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SE</td>
<td>Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SG</td>
<td>Singapore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
<td>SK</td>
<td>Slovakia</td>
<td>SN</td>
<td>Senegal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
<td>TG</td>
<td>Togo</td>
<td>TJ</td>
<td>Tajikistan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TM</td>
<td>Turkmenistan</td>
<td>TR</td>
<td>Turkey</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>Ukraine</td>
<td>TW</td>
<td>Taiwan</td>
<td>VI</td>
<td>Vietnam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
<td>TW</td>
<td>Taiwan</td>
<td>VU</td>
<td>Uzbekistan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VN</td>
<td>Viet Nam</td>
<td>YU</td>
<td>Yugoslavia</td>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TITLE OF THE INVENTION
DNA MOLECULES ENCODING THE MELANOCORTIN 5 RECEPTOR
PROTEIN FROM RHESUS MONKEY

CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority to U.S. Serial No. 60/107,632,
filed November 9, 1998, which is hereby incorporated by reference.

FIELD OF THE INVENTION
The present invention relates to rhesus monkey (*Macaca mulatta*)
DNA molecules encoding the melanocortin-5 receptor protein belonging to the
rhodopsin sub-family of G-protein coupled receptors, recombinant vectors comprising
DNA molecules encoding rhesus MC-5R, recombinant host cells which contain a
recombinant vector encoding rhesus MC-5R, the rhesus MC-5R protein encoded by
the DNA molecule, and methods of identifying selective agonists and antagonists of
rhesus MC-5R.

BACKGROUND OF THE INVENTION
Melanocortin receptors belong to the rhodopsin sub-family of G-
protein coupled receptors (GPCR’s). Five different subtypes are known. These
melanocortin receptors bind and are activated by peptides such as α-, β, or γ-
melanocyte stimulating hormones (α-, β-, γ-MSH) derived from the pro-
opiomelanocortin (POMC) gene. A wide range of physiological functions are
believed to be mediated by melanocortin peptides and their receptors.

U.S. Patent No. 5,532,347, issued on July 2, 1996, to Cone and
Mountjoy discloses human and mouse DNA molecules which encode MC-1R (also
known in the art as α-MSH-R). The expressed human protein contains 317 amino
acids.

U.S. Patent No. 5,280,112 (issued January 18, 1994) and U.S. Patent
No. 5,554,729 (issued September 10, 1996), both to Cone and Mountjoy, disclose
human and mouse DNA molecules which encode MC-2R (also known in the art as

molecules and the concomitant protein for human MC-1R and human MC-2R.


Fathi, et al. (1995, *Neurochemical Research* 20(1):107-113) also disclose a DNA molecule thought to encode human MC-5R. There are several sequence discrepancies when compared to the DNA molecule disclosed by Chhajlani, et al., *id*.


In rodents, MC-4R has been implicated as a key regulator of feeding behavior which regulates body weight through studies with peptide agonists and antagonists (Fan et al., 1997, *Nature* 385: 165-168) and with a MC-4R knock-out mouse (Huszar et al., 1997, *Cell* 88: 131-141).

Compounds that bind to such receptors were previously identified by binding to human and/or rodent receptors and evaluated for their efficacy in rodents. However, the neuroendocrine process can differ between rodents and man. It is also
expected that some compounds exhibit different binding affinities for different species homologues of the same receptor (Fong et al., 1992, *J. Biol. Chem.* 267:25666-25671; Hartig et al., 1992, *TIPS* 13:152-159).

Before compounds can be selected as a drug candidate it is first evaluated for a physiological effect in rodents and then in the rhesus primate. It is often that one compound may be effective in one animal species but not in another. Previously, it has been impossible to determine if the failure was due to an altered melanocortin pathway in different species, or due to a compound's having a lower affinity for one particular species. Past protocols required the use of a rhesus brain membrane to determine the in vitro biochemical activity of compounds, if such protocol could be successfully employed.

It is desirable to correlate *in vivo* data with *in vitro* biochemical activity of compounds.

It is also desirable to first select compounds that are active for the rhesus receptor *in vitro*.

It is also desirable to identify compounds which can determine the relevance of receptor targets in rhesus and allow selection of novel drugs to treat obesity.

It is further desirable to discover new drugs which effect pathophysiological processes by modulating the effects in rhesus to identify melanocortin active process in primates, followed by human clinical trials.

The present invention addresses and meets these needs by disclosing an isolated nucleic acid fragment which expresses a form of rhesus MC-5R, recombinant vectors which house this nucleic acid fragment, recombinant host cells which expresses rhesus MC-5R and/or a biologically active equivalent, and pharmacological properties of this rhesus MC-5R protein.

**SUMMARY OF THE INVENTION**

The present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel rhesus monkey (*Macaca mulatta*) melanocortin-5 receptor (rhMC-5R). The nucleic acid molecules of the present invention are substantially free from other nucleic acids.

The present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes mRNA which expresses a novel rhesus MC-5R, this
DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:1.

The present invention also relates to biologically active fragments or mutants of SEQ ID NO:1 which encodes mRNA expressing a novel rhesus MC-5R. Any such biologically active fragment and/or mutant will encode either a protein or protein fragment which at least substantially mimics the pharmacological properties of a wild-type MC-5R protein, including but not limited to the rhesus MC-5R receptor protein as set forth in SEQ ID NO:2. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for MC-5R function.

A preferred aspect of this portion of the present invention is disclosed in Figure 1, a rhesus cDNA molecule encoding a novel MC-5R (SEQ ID NO:1).

The isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.

The present invention also relates to subcellular membrane fractions of the recombinant host cells (both prokaryotic and eukaryotic as well as both stably and transiently transformed cells) which contain the proteins encoded by the nucleic acids of the present invention. These subcellular membrane fractions will comprise either wild-type or mutant forms of rhesus melanocortin-5 receptor proteins at levels substantially above endogenous levels and hence will be useful in various assays described throughout this specification.

The present invention also relates to a substantially purified form of the rhesus melanocortin-5 receptor protein, which comprises the amino acid sequence disclosed in Figure 2 and set forth as SEQ ID NO:2. A preferred aspect of the present
invention is disclosed in Figure 2 and is set forth as SEQ ID NO:2, the amino acid sequence of the novel rhesus melanocortin-5 receptor protein.

The present invention also relates to biologically active fragments and/or mutants of the rhesus melanocortin-5 receptor protein comprising the amino acid sequence set forth as SEQ ID NO:2, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for MC-5R function.

The present invention also relates to isolated nucleic acid molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type vertebrate MC-5R activity. A preferred aspect of this portion of the invention includes, but is not limited to, glutathione S-transferase (GST)-MC-5R fusion constructs which include, but are not limited to, either the intracellular domain of rhesus MC-5R as an in-frame fusion at the carboxy terminus of the GST gene, or the extracellular and transmembrane ligand binding domain of MC-5R fused to the amino terminus of GST, or the extracellular and transmembrane domain of MC-5R fused to an immunoglobulin gene by methods known to one of ordinary skill in the art. Soluble recombinant GST-MC-5R fusion proteins may be expressed in various expression systems, including Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (pAcG2T, Pharmingen).

Therefore, the present invention relates to methods of expressing the rhesus MC-5R protein and biological equivalents disclosed herein, assays employing these gene products, recombinant host cells which comprise DNA constructs which express these receptor proteins, and compounds identified through these assays which act as agonists or antagonists of MC-5R activity.

The present invention also relates to polyclonal and monoclonal antibodies raised in response to either the rhesus form of MC-5R, or a biologically active fragment thereof.

It is an object of the present invention to provide an isolated nucleic acid molecule which encodes a novel form of rhesus MC-5R, or rhesus MC-5R fragments, mutants or derivatives of SEQ ID NO:2. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions,
amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for vertebrate MC-5R function.

It is a further object of the present invention to provide the rhesus MC-5R proteins or protein fragments encoded by the nucleic acid molecules referred to in the preceding paragraph.

It is a further object of the present invention to provide recombinant vectors and recombinant host cells which comprise a nucleic acid sequence encoding rhesus MC-5R or a biological equivalent thereof.

It is an object of the present invention to provide a substantially purified form of the rhesus MC-5R protein, as set forth in SEQ ID NO:2.

It is an object of the present invention to provide for biologically active fragments and/or mutants of the rhesus MC-5R protein, such as set forth in SEQ ID NO:2, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.

It is also an object of the present invention to provide for MC-5R-based assays to select for modulators of this receptor protein. These assays are preferably cell based assays whereby a DNA molecule encoding rhMC-5R is transfected or transformed into a host cell, this recombinant host cell is allowed to grow for a time sufficient to express MC-5R prior to use in various assays described herein.

It is a further object to provide for membrane preparations from host cells transfected or transformed with a DNA molecule encoding rhMC-5R for use in assays to select for modulators of MC-5R activity.

It is also an object of the present invention to provide for MC-5R-based in-frame fusion constructions, methods of expressing these fusion constructs, biological equivalents disclosed herein, related assays, recombinant cells expressing these constructs, and agonistic and/or antagonistic compounds identified through the use of the nucleic acid encoding vertebrate MC-5R protein as well as the expressed protein.

As used herein, "rh" or refers to --rhesus--.
As used herein, "MC-5R" refers to melanocortin 5 receptor--.
As used herein, "GPCR" refers to G-protein coupled receptor--.
Whenever used herein, the term "mammalian host" will refer to any mammal, including a human being.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the nucleotide sequence which encodes rhesus MC-5R, as set forth in SEQ ID NO:1.

Figure 2A and Figure 2B show the amino acid sequence of rhesus MC-5R as set forth in SEQ ID NO:2, as well as the open reading frame which encodes rhMC-5R, which is comprised within SEQ ID NO:1.

Figure 3A and Figure 3B show characterization of rhesus MC-5R. Figure 3A shows inhibition of [125I]NDP-α-MSH binding by NDP-α-MSH, γ2-MSH or Shu-9119. Figure 3B shows stimulation of cAMP synthesis in response to NDP-α-MSH or γ2-MSH. Each curve represents a typical experiment with duplicate measurements. Average data from multiple experiments are listed in Table 1.

Figure 4 shows the comparison of binding affinity (IC50) and activation potency (EC50) for the MC-5R from 2 species. Abbreviations are as follows: A, human ACTH(1-24); α, α-MSH; γ, γ2-MSH; M, MT-II; N, NDP-α-MSH.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel rhesus monkey (Macaca mulatta) melanocortin-5 receptor (rhMC-5R). The nucleic acid molecules of the present invention are substantially free from other nucleic acids. For most cloning purposes, DNA is a preferred nucleic acid.

The present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes mRNA which expresses a novel rhesus MC-5R, this DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:1, shown herein as follows:

GCTGCTCTTC TTTGTAACC TCTCTGGATT GTGAATTTAA AATGTGTTTT ACAAGTAAATT TGCTGCCAAG ACAAGAGGTT GATTTCTCCA GCAATGAATT CCTCTTTTCA CCTGCATTTC TTGGATCTCA ACCTGAATGC CACAGAGGGC AACCTTTTCAG CACCCAGTGT CAGAAAACAG TCTTGGCCCT GTGAAAACAT GGCCATGGC7 GTGGAGGTGT TTCTCACTCT GGGTGCCATC
AGCCTCGTGG AGAACATCTT GTTATAGGG GCCATAGTGA AGAACAAAAA CCGCAGATGC
CCCATGTACT TCTTCTGATG CAGCCTTGCG GTGGCCGACA TGCTGTTGAG CATGTCCCAAC
GACCTGGGAGA CACATCCACCT CTACCTTCTC AACAAACAAG ACCTAAGTAT AGCAGAGGCC
TTGTTGGGCC ACATGGACAA GCTGTTTGGAC TCCATGATCT GCAATTTCCGT GGTGGCGTCC
ATGTTCAAGCT TGCTGGCCAT TGCCGTTGGAT AGGTACGTCA CCTCTTCTTA TGCCCTCGCGC
TACACCCCA CACATCACGGC AGGGCGCTCG GGGCCCATCA TGCGCGGCAT CCGGCGTTTTC
TGACCAGCGT GGCCGACGGTG GCTCAACCGG TACCCCGAGT CCACTTCATG CATCCTCGGCG
CTCATCTCCA TGTTCTCCAC GATGGCTCTTC CTCCCAGGGTG GTCTGTGATC ACACATGTTTCC
CTCCTGGGCG GGACTCAAGG CAAAGGGATG CCGGCTCTCG CCGGGCAGCG CTTGGCGGGG
(CSEQ ID NO:1).

The above-exemplified isolated DNA molecule, shown in Figure 1 and set forth as SEQ ID NO:1, contains 1080 nucleotides. This DNA molecule contains an open reading frame from nucleotide 94 to nucleotide 1068, with a "TAG" termination codon from nucleotides 1069-1071. This open reading frame encodes a rhesus MC-5R protein 325 amino acids in length, as shown in Figure 2 and as set forth in SEQ ID NO:2.

The present invention also relates to biologically active fragments or mutants of SEQ ID NO:1 which encodes mRNA expressing a novel rhesus MC-5R. Any such biologically active fragment and/or mutant will encode either a protein or a protein fragment which at least substantially mimics the pharmacological properties of a wild-type MC-5R protein, including but not limited to the rhesus MC-5R receptor protein as set forth in SEQ ID NO:2. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for MC-5R function.

A preferred aspect of this portion of the present invention is disclosed in Figure 1, a rhesus cDNA molecule encoding a novel MC-5R (SEQ ID NO:1).
The isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

It is known that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences encode RNA comprising alternative codons which code for the eventual translation of the identical amino acid, as shown below:

A=Ala=Alanine: codons GCA, GCC, GCG, GCU
C=Cys=Cysteine: codons UGC, UGU
D=Asp=Aspartic acid: codons GAC, GAU
E=Glu=Glutamic acid: codons GAA, GAG
F=Phe=Phenylalanine: codons UUC, UUU
G=Gly=Glycine: codons GGA, GGC, GGG, GGU
H=His=Histidine: codons CAC, CAU
I=Ile=Isoleucine: codons AUA, AUC, AUU
K=Lys=Lysine: codons AAA, AAG
L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU
M=Met=Methionine: codon AUG
N=Asp=Asparagine: codons AAC, AAU
P=Pro=Proline: codons CCA, CCC, CCG, CCU
Q=Gln=Glutamine: codonsCAA, CAG
R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU
S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU
T=Thr=Threonine: codons ACA, ACC, ACG, ACU
V=Val=Valine: codons GUA, GUC, GUG, GUU
W=Trp=Tryptophan: codon UGG
Y=Tyr=Tyrosine: codons UAC, UAU

Therefore, the present invention discloses codon redundancy which may result in differing DNA molecules expressing an identical protein. For purposes of this specification, a sequence bearing one or more replaced codons
will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.

It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally occurring peptide. Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.

Any of a variety of procedures may be used to clone rhesus MC-5R. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, Proc. Natl. Acad. Sci. USA 85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of rhesus MC-5R cDNA. These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the rhesus MC-5R cDNA following the construction of a rhesus MC-5R-containing cDNA library in an appropriate expression vector system; (3) screening a rhesus MC-5R-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the rhesus MC-5R protein; (4) screening a rhesus MC-5R-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the rhesus MC-5R protein. This partial cDNA is obtained by the specific PCR amplification of rhesus MC-5R DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other kinases which are related to the rhesus MC-5R protein; (5) screening a rhesus MC-5R-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA or oligonucleotide with homology to a mammalian MC-5R protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of rhesus MC-5R cDNA.
identified as an EST as described above; or (6) designing 5’ and 3’ gene specific oligonucleotides using SEQ ID NO: 1 as a template so that either the full-length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding rhesus MC-5R.

It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cell types or species types, may be useful for isolating a rhesus MC-5R-encoding DNA or a rhesus MC-5R homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other rhesus cells.

It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have MC-5R activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding rhesus MC-5R may be done by first measuring cell-associated MC-5R activity using any known assay available for such a purpose.

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene.

It is also readily apparent to those skilled in the art that DNA encoding rhesus MC-5R may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Sambrook, et al., supra.

In order to clone the rhesus MC-5R gene by one of the preferred methods, the amino acid sequence or DNA sequence of rhesus MC-5R or a homologous protein may be necessary. To accomplish this, the MC-5R protein or a homologous protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be
determined for the PCR amplification of a partial rhesus MC-5R DNA fragment. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized. Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the rhesus MC-5R sequence but others in the set will be capable of hybridizing to rhesus MC-5R DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still sufficiently hybridize to the rhesus MC-5R DNA to permit identification and isolation of rhesus MC-5R encoding DNA. Alternatively, the nucleotide sequence of a region of an expressed sequence may be identified by searching one or more available genomic databases. Gene-specific primers may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs. As noted above, the appropriate nucleotide sequence for use in a PCR-based method may be obtained from SEQ ID NO:1, either for the purpose of isolating overlapping 5′ and 3′ RACE products for generation of a full-length sequence coding for rhesus MC-5R, or to isolate a portion of the nucleotide sequence coding for rhesus MC-5R for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence encoding rhesus MC-5R or rhesus MC-5R-like proteins.

Included in the present invention are DNA sequences that hybridize to SEQ ID NO:1 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hours to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt’s solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography. Other procedures using conditions of high stringency would include either a hybridization step carried out in 5X SSC, 5X Denhardt’s solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.
Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, e.g., Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

Melanocortin receptors belong to the rhodopsin sub-family of GPCR’s. However, several features in the rhMC-5R are shared with all other receptors and are absent in most other GPCR’s, including the EN motif in TM1, the lack of Cys in the loop between TM2 and TM3 or between TM4 and TM5, the MxxxxxyY motif in TM5, and the DPxxY motif in TM7. Since all melanocortin receptors lack Cys residues in the extracellular loops that are present in other members of the rhodopsin sub-family, interhelical disulfide bond (e.g., between the Cys residues near the top of TM3 and TM5) may play the same function as interloop disulfide bond in most other GPCR’s.

The present invention also relates to a substantially purified form of the rhesus melanocortin-5 receptor protein, which comprises the amino acid sequence is disclosed in Figure 2 and set forth as SEQ ID NO:2.

The present invention also relates to biologically active fragments and/or mutants of the rhesus melanocortin-5 receptor protein comprising the amino acid sequence set forth as SEQ ID NO:2, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for MC-5R function.

A preferred aspect of the present invention is disclosed in Figure 2 and is set forth as SEQ ID NO:2, and as herein set forth as follows:

```
MGMSFHLHFLDLNLANTEGRNLTPSVMKSSPCEN
MGMAFVFLTGLGAISSLVENILVIGAIVKKNKLNHC
MYFFVCSLAVADMVLVSMSNWETTYYLLNNKHLV
IADAFVRHIDNVFDSDMICISVVASMCSLLAIADV
YTVFVYALRYHHTARRSGAIAGICWAFCTCGI
VFILYSESSTYVILCISMMFTMLFLLVCLYIHMFL
LARTHAKRMAALPGASSARQRSTSVOGAVTLLMTLLG
```
As with many receptor proteins, it is possible to modify many of the amino acids, particularly those which are not found in the ligand binding domain, and still retain substantially the same biological activity as the original receptor. Thus this invention includes modified rhMC-5R polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as rhMC-5R. It is generally accepted that single amino acid substitutions do not usually alter the biological activity of a protein (see, e.g., Molecular Biology of the Gene, Watson et al., 1987, Fourth Ed., The Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham & Wells, 1989, Science 244:1081-1085). Accordingly, the present invention includes isolated nucleic acid molecules and expressed MC-5R proteins wherein one amino acid substitution is generated and which this protein retains substantially the same biological activity as wild-type rhMC-5R. The present invention also includes isolated nucleic acid molecules and expressed MC-5R proteins wherein two or more amino acid substitution is generated wherein this protein retains substantially the same biological activity as wild-type rhMC-5R. In particular, the present invention includes embodiments where the above-described substitutions are conservative substitutions. In particular, the present invention includes embodiments where the above-described substitutions do not occur in the ligand-binding domain of rhMC-5R.

Following expression of MC-5R in a host cell, MC-5R protein may be recovered to provide MC-5R protein in active form. Several MC-5R protein purification procedures are available and suitable for use. Recombinant MC-5R protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. In addition, recombinant MC-5R protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length MC-5R protein, or polypeptide fragments of MC-5R protein.
The present invention also relates to isolated nucleic acid molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type vertebrate MC-5R activity. A preferred aspect of this portion of the invention includes, but is not limited to, glutathione S-transferase (GST)-MC-5R fusion constructs which include, but are not limited to, either the intracellular domain of rhesus MC-5R as an in-frame fusion at the carboxy terminus of the GST gene or the extracellular and transmembrane ligand binding domain of MC5R fused to an GST or immunoglobulin gene by methods known to one of ordinary skill in the art. Recombinant GST-MC-5R fusion proteins may be expressed in various expression systems, including Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (pAcG2T, Pharmingen).

The present invention also relates to subcellular membrane fractions from the recombinant host cells (both prokaryotic and eukaryotic as well as both stably and transiently transformed cells) which contain the nucleic acids of the present invention. These subcellular membrane fractions will comprise either wild-type or mutant forms of rhesus melanocortin-5 receptor proteins at levels substantially above endogenous levels and hence will be useful in various assays described throughout this specification.

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification. The nucleic acid molecules of the present invention encoding rhMC-5R, in whole or in part, can be linked with other DNA molecules, i.e., DNA molecules to which the rhMC-5R are not naturally linked, to form "recombinant DNA molecules" containing the receptor. The novel DNA sequences of the present invention can be inserted into vectors which comprise nucleic acids encoding a rhMC-5R or a functional equivalent. These vectors may be comprised of DNA or RNA; for most cloning purposes DNA vectors are preferred. Typical vectors include plasmids, modified viruses, bacteriophage and cosmids, yeast artificial chromosomes and other forms of episomal or integrated DNA that can encode a rhMC-5R. It is well within the skilled artisan to determine an appropriate vector for a particular gene transfer or other use.

To this end, the present invention also includes vectors containing an rhMC-5R gene, host cells containing the vectors, and methods of making
substantially pure rhMC-5R protein comprising the steps of introducing the rhMC-5R
5
gene into a host cell, and cultivating the host cell under appropriate conditions such
that rhMC-5R is produced. The rhMC-5R so produced may be harvested from the
host cells in conventional ways. Therefore, the present invention also relates to
methods of expressing the rhesus MC-5R protein and biological equivalents disclosed
herein, assays employing these gene products, recombinant host cells which comprise
DNA constructs which express these receptor proteins, and compounds identified
through these assays which act as agonists or antagonists of MC-5R activity.
10
The cloned rhesus MC-5R cDNA obtained through the methods
described above may be recombinantly expressed by molecular cloning into an
expression vector (such as pcDNA3.neo, pcDNA3.1, pCR2.1, pBlueBacHis2 or
pLITMUS28) containing a suitable promoter and other appropriate transcription
regulatory elements, and transferred into prokaryotic or eukaryotic host cells to
15
produce recombinant rhesus MC-5R. Techniques for such manipulations can be
found described in Sambrook, et al., supra, are discussed at length in the Example
section and are well known and easily available to the artisan of ordinary skill in the
art.

A variety of mammalian expression vectors may be used to express
recombinant rhesus MC-5R in mammalian cells. Expression vectors are defined
20
herein as DNA sequences that are required for the transcription of cloned DNA and
the translation of their mRNAs in an appropriate host. Such vectors can be used to
express eukaryotic DNA in a variety of hosts such as bacteria, blue green algae, plant
cells, insect cells and animal cells. Specifically designed vectors allow the shuttling
of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An
appropriately constructed expression vector should contain: an origin of replication
25
for autonomous replication in host cells, selectable markers, a limited number of
useful restriction enzyme sites, a potential for high copy number, and active
promoters. A promoter is defined as a DNA sequence that directs RNA polymerase
to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes
mRNAs to be initiated at high frequency. Expression vectors may include, but are
30
not limited to, cloning vectors, modified cloning vectors, specifically designed
plasmids or viruses. Commercially available mammalian expression vectors which
may be suitable for recombinant rhesus MC-5R expression, include but are not
limited to, pcDNA3.neo (Invitrogen), pcDNA3.1 (Invitrogen), pCI-neo (Promega),

- 16 -
pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Bioiabs),
pcDNA1, pcDNA1amp (Invitrogen), pcDNA3 (Invitrogen), pMC1neo (Stratagene),
pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2)
(ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199),
RSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and
λZD35 (ATCC 37565).

Also, a variety of bacterial expression vectors may be used to express
recombinant rhesus MC-5R in bacterial cells. Commercially available bacterial
expression vectors which may be suitable for recombinant rhesus MC-5R expression
include, but are not limited to pCR2.1 (Invitrogen), pET11a (Novagen), lambda gt11
(Invitrogen), and pKK223-3 (Pharmacia).

In addition, a variety of fungal cell expression vectors may be used to
express recombinant rhesus MC-5R in fungal cells. Commercially available fungal
cell expression vectors which may be suitable for recombinant rhesus MC-5R
expression include but are not limited to pYES2 (Invitrogen) and Pichia expression
vector (Invitrogen).

Also, a variety of insect cell expression vectors may be used to express
recombinant receptor in insect cells. Commercially available insect cell expression
vectors which may be suitable for recombinant expression of rhesus MC-5R include
but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen), and pAcG2T
(Pharmingen).

Expression of rhesus MC-5R DNA may also be performed using in
vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in
various cell-free systems, including but not limited to wheat germ extracts and
reticulocyte extracts, as well as efficiently translated in cell based systems, including
but not limited to microinjection into frog oocytes, with microinjection into frog
oocytes being preferred.

To determine the rhesus MC-5R cDNA sequence(s) that yields optimal
levels of rhesus MC-5R, cDNA molecules including but not limited to the following
can be constructed: a cDNA fragment containing the full-length open reading frame
for rhesus MC-5R as well as various constructs containing portions of the cDNA
encoding only specific domains of the protein or rearranged domains of the protein.
All constructs can be designed to contain none, all or portions of the 5' and/or 3'
untranslated region of a rhesus MC-5R cDNA. The expression levels and activity of
rhesus MC-5R can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the rhesus MC-5R cDNA cassette yielding optimal expression in transient assays, this MC-5R cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells.

Therefore, another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding the rhMC-5R. Such recombinant host cells can be cultured under suitable conditions to produce rhMC-5R or a biologically equivalent form. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as E. coli, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to Drosophila and silkworm derived cell lines. Therefore, an expression vector containing DNA encoding a rhesus MC-5R-like protein may be used for expression of rhesus MC-5R in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as E. coli, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to Drosophila- and silkworm-derived cell lines. For instance, one insect expression system utilizes Spodoptera frugiperda (Sf21) insect cells (Invitrogen) in tandem with a baculovirus expression vector (pAcG2T, Pharmingen). Also, mammalian species which may be suitable and which are commercially available, include but are not limited to, L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), Saos-2 (ATCC HTB-85), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127i (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171) and CPAE (ATCC CCL 209). The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are individually analyzed to determine whether they produce rhesus MC-5R protein. Identification of rhesus MC-5R expressing cells may be done by several means, including but not limited to immunological reactivity with anti-rhesus MC-5R
antibodies, labeled ligand binding and the presence of host cell-associated rhesus MC-5R activity.

The assays described herein as well as protein purification schemes can be carried out with cells that have been transiently or stably transfected or transformed with an expression vector which directs expression of MC-5R. The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. Transformation is meant to encompass a genetic change to the target cell resulting from an incorporation of DNA. Transfection is meant to include any method known in the art for introducing MC-5R into the test cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct containing MC-5R, and electroporation. The expression vector-containing cells are individually analyzed to determine whether they produce human MC-5R protein. Identification of human MC-5R expressing cells may be done by several means, including but not limited to immunological reactivity with anti-human MC-5R antibodies, labeled ligand binding and the presence of host cell-associated human MC-5R activity.

The specificity of binding of compounds showing affinity for rhMC-5R is shown by measuring the affinity of the compounds for recombinant cells expressing the cloned receptor or for membranes from these cells. Expression of the cloned receptor and screening for compounds that bind to rhMC-5R or that inhibit the binding of a known, radiolabeled ligand of rhMC-5R to these cells, or membranes prepared from these cells, provides an effective method for the rapid selection of compounds with high affinity for rhMC-5R. Such ligands need not necessarily be radiolabeled but can also be nonisotopic compounds that can be used to displace bound radiolabeled compounds or that can be used as activators in functional assays. Compounds identified by the above method are likely to be agonists or antagonists of rhMC-5R and may be peptides, proteins, or non-proteinaceous organic molecules.

Accordingly, the present invention is directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding a MC-5R protein as well as compounds which effect the function of the MC-5R protein. Methods for identifying agonists and antagonists of other receptors are well known in the art and can be adapted to identify agonists and antagonists of MC-5R. For example, Cascieri et al. (1992, Molec. Pharmacol. 41:1096-1099) describe a method...
for identifying substances that inhibit agonist binding to rat neurokinin receptors and thus are potential agonists or antagonists of neurokinin receptors. The method involves transfecting COS cells with expression vectors containing rat neurokinin receptors, allowing the transfected cells to grow for a time sufficient to allow the neurokinin receptors to be expressed, harvesting the transfected cells and resuspending the cells in assay buffer containing a known radioactively labeled agonist of the neurokinin receptors either in the presence or the absence of the substance, and then measuring the binding of the radioactively labeled known agonist of the neurokinin receptor to the neurokinin receptor. If the amount of binding of the known agonist is less in the presence of the substance than in the absence of the substance, then the substance is a potential agonist or antagonist of the neurokinin receptor. Where binding of the substance such as an agonist or antagonist to MC-5R is measured, such binding can be measured by employing a labeled substance or agonist. The substance or agonist can be labeled in any convenient manner known to the art, e.g., radioactively, fluorescently, enzymatically.

Therefore, the specificity of binding of compounds having affinity for MC-5R is shown by measuring the affinity of the compounds for recombinant cells expressing the cloned receptor or for membranes from these cells. Expression of the cloned receptor and screening for compounds that bind to MC-5R or that inhibit the binding of a known, radiolabeled ligand of MC-5R to these cells, or membranes prepared from these cells, provides an effective method for the rapid selection of compounds with high affinity for MC-5R. Such ligands need not necessarily be radiolabeled but can also be nonisotopic compounds that can be used to displace bound radiolabeled compounds or that can be used as activators in functional assays. Compounds identified by the above method are likely to be agonists or antagonists of MC-5R and may be peptides, proteins, or non-proteinaceous organic molecules. Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding MC-5R, or by acting as an agonist or antagonist of the MC-5R receptor protein. These compounds that modulate the expression of DNA or RNA encoding MC-5R or the biological function thereof may be detected by a variety of assays. The assay may be a simple "yes/no" assay to determine whether there is a change in expression or function. The assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in
a standard sample. Kits containing MC-5R, antibodies to MC-5R, or modified MC-5R may be prepared by known methods for such uses.

Therefore, the present invention relates to methods of expressing rhMC-5R in recombinant systems and of identifying agonists and antagonists of rhMC-5R. When screening compounds in order to identify potential pharmaceuticals that specifically interact with a target receptor, it is necessary to ensure that the compounds identified are as specific as possible for the target receptor. To do this, it is necessary to screen the compounds against as wide an array as possible of receptors that are similar to the target receptor. Thus, in order to find compounds that are potential pharmaceuticals that interact with receptor A, it is necessary not only to ensure that the compounds interact with receptor A (the “plus target”) and produce the desired pharmacological effect through receptor A, it is also necessary to determine that the compounds do not interact with receptors B, C, D, etc. (the “minus targets”). In general, as part of a screening program, it is important to have as many minus targets as possible (see Hodgson, 1992, Bio/Technology 10:973-980). Rhesus MC-5R proteins and the DNA molecules encoding this receptor protein have the additional utility in that they can be used as “minus targets” in screens designed to identify compounds that specifically interact with other G-protein coupled receptors. Due to homology to GPCRs, the rhMC-5R of this invention is believed to function similarly to GPCRs and have similar biological activity. They are useful in understanding the biological and physiological effects in the rhesus to in identify melanocortin active process in primates, followed by human clinical trials. More notable, rhMC-5R agonists will be identified and evaluated for their effects on food intake, weight gain, and metabolic rate to identify novel-anti-obesity agents that are effective in primates. They may also be used to scan for rhesus monkey melanocortin agonists and antagonists; as in particular to test the specificity of identified ligands.

To this end, the present invention relates in part to methods of identifying a substance which modulates MC-5R receptor activity, which involves:

(a) combining a test substance in the presence and absence of a MC-5R receptor protein wherein said MC-5R receptor protein comprises the amino acid sequence as set forth in SEQ ID NO:2; and,
(b) measuring and comparing the effect of the test substance in the presence and absence of the MC-5R receptor protein.
In addition, several specific embodiments are disclosed herein to show the diverse type of screening or selection assay which the skilled artisan may utilize in tandem with an expression vector directing the expression of the MC-5R receptor protein. Methods for identifying agonists and antagonists of other receptors are well known in the art and can be adapted to identify agonists and antagonists of MC-5R. Therefore, these embodiments are presented as examples and not as limitations. To this end, the present invention includes assays by which MC-5R modulators (such as agonists and antagonists) may be identified. Accordingly, the present invention includes a method for determining whether a substance is a potential agonist or antagonist of MC-5R that comprises:

(a) transfecting or transforming cells with an expression vector that directs expression of MC-5R in the cells, resulting in test cells;

(b) allowing the test cells to grow for a time sufficient to allow MC-5R to be expressed;

(c) exposing the cells to a labeled ligand of MC-5R in the presence and in the absence of the substance;

(d) measuring the binding of the labeled ligand to MC-5R; where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then the substance is a potential agonist or antagonist of MC-5R.

The conditions under which step (c) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C. The test cells may be harvested and resuspended in the presence of the substance and the labeled ligand. In a modification of the above-described method, step (c) is modified in that the cells are not harvested and resuspended but rather the radioactively labeled known agonist and the substance are contacted with the cells while the cells are attached to a substratum, e.g., tissue culture plates.

The present invention also includes a method for determining whether a substance is capable of binding to MC-5R, i.e., whether the substance is a potential agonist or an antagonist of MC-5R, where the method comprises:

(a) transfecting or transforming cells with an expression vector that directs the expression of MC-5R in the cells, resulting in test cells;
(b) exposing the test cells to the substance;
(c) measuring the amount of binding of the substance to MC-5R;
(d) comparing the amount of binding of the substance to MC-5R in the test cells with the amount of binding of the substance to control cells that have not been transfected with MC-5R;

wherein if the amount of binding of the substance is greater in the test cells as compared to the control cells, the substance is capable of binding to MC-5R. Determining whether the substance is actually an agonist or antagonist can then be accomplished by the use of functional assays such as, e.g., the assay involving the use of promiscuous G-proteins described below.

The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C. The test cells are harvested and resuspended in the presence of the substance.

Chen et al. (1995, Analytical Biochemistry 226: 349-354) describe a colorometric assay which utilizes a recombinant cell transfected with an expression vector encoding a G-protein coupled receptor with a second expression vector containing a promoter with a cAMP responsive element fused to the LacZ gene. Activity of the overexpressed G-protein coupled receptor is measured as the expression and OD measurement of β-Gal. Therefore, another aspect of this portion of the invention includes a non-radioactive method for determining whether a substance is a potential agonist or antagonist of MC-5R that comprises:

(a) transfecting or transforming cells with an expression vector encoding MC-5R, resulting in test cells;
(b) transfecting or transforming the test cells of step (a) with an expression vector which comprises a cAMP-inducible promoter fused to a colorometric gene such a LacZ;
(c) allowing the transfected cells to grow for a time sufficient to allow MC-5R to be expressed;
(d) harvesting the transfected cells and resuspending the cells in the presence of a known agonist of MC-5R and/or in both the presence and absence of the test compound;
(e) measuring the binding of the known agonist and test compound to overexpressed MC-5R by a colorometric assay which measures expression off the cAMP-inducible promoter and comparing expression levels in the presence of the known agonist as well as in the presence and absence of the unknown substance so as to determine whether the unknown substance acts as either a potential agonist or antagonist of MC-5R.

Additional methods of identifying agonists or antagonists include but are by no means limited to the following:

I. (a) transfecting or transforming cells with a first expression vector which directs expression of MC-5R and a second expression vector which directs the expression of a promiscuous G-protein, resulting in test cells;
    (b) exposing the test cells to a substance that is a suspected agonist of MC-5R;
    (c) measuring the level of inositol phosphates in the cells;
    where an increase in the level of inositol phosphates in the cells as compared to the level of inositol phosphates in the cells in the absence of the suspected agonist indicates that the substance is an agonist of MC-5R.

II. (a) transfecting or transforming cells with a first expression vector which directs expression of MC-5R and a second expression vector which directs the expression of a promiscuous G-protein, resulting in test cells;
    (b) exposing the test cells to a substance that is an agonist of MC-5R;
    (c) subsequently or concurrently to step (b), exposing the test cells to a substance that is a suspected antagonist of MC-5R;
    (d) measuring the level of inositol phosphates in the cells;
    where a decrease in the level of inositol phosphates in the cells in the presence of the suspected antagonist as compared to the level of inositol phosphates in the cells in the absence of the suspected antagonist indicates that the substance is an antagonist of MC-5R.

III. the method of II wherein the first and second expression vectors of step (a) are replaced with a single expression vector which expresses a chimeric MC-5R protein fused at its C-terminus to a promiscuous G-protein.

The above-described methods can be modified in that, rather than exposing the test cells to the substance, membranes can be prepared from the test cells
and those membranes can be exposed to the substance. Such a modification utilizing membranes rather than cells is well known in the art and is described in, e.g., Hess et al., 1992, Biochem. Biophys. Res. Comm. 184:260-268. Accordingly, another embodiment of the present invention includes a method for determining whether a substance binds and/or is a potential agonist or antagonist of MC-5R wherein membrane preparations from the test cells are utilized in place of the test cells. Such methods comprise the following and may utilized the physiological conditions as noted above:

(a) transfecting or transforming cells with an expression vector that directs the expression of MC-5R in the cells, resulting in test cells;
(b) preparing membranes containing MC-5R from the test cells and exposing the membranes to a ligand of MC-5R under conditions such that the ligand binds to the MC-5R in the membranes;
(c) subsequently or concurrently to step (b), exposing the membranes from the test cells to a substance;
(d) measuring the amount of binding of the ligand to the MC-5R in the membranes in the presence and the absence of the substance;
(e) comparing the amount of binding of the ligand to MC-5R in the membranes in the presence and the absence of the substance where a decrease in the amount of binding of the ligand to MC-5R in the membranes in the presence of the substance indicates that the substance is capable of binding to MC-5R.

The present invention also relates to a method for determining whether a substance is capable of binding to MC-5R comprising:
(a) transfecting or transforming cells with an expression vector that directs the expression of MC-5R in the cells, resulting in test cells;
(b) preparing membranes containing MC-5R from the test cells and exposing the membranes from the test cells to the substance;
(c) measuring the amount of binding of the substance to the MC-5R in the membranes from the test cells;
(d) comparing the amount of binding of the substance to MC-5R in the membranes from the test cells with the amount of binding of the substance to membranes from control cells that have not been transfected with MC-5R, where if the amount of binding of the substance to MC-5R in the membranes from the test
cells is greater than the amount of binding of the substance to the membranes from the control cells, then the substance is capable of binding to MC-5R.

A preferred embodiment of the present invention is determining various ligand binding affinities using $^{125}\text{I}$-labeled NDP-α-MSH as the labeled ligand in the presence of varying concentration of unlabeled ligands. The activation of the second messenger pathway may be determined by measuring the intracellular cAMP elicited by agonist at various concentration.

The present invention also relates to polyclonal and monoclonal antibodies raised in response to either the rhesus form of MC-5R, or a biologically active fragment thereof. Polyclonal or monoclonal antibodies may be raised against rhesus MC-5R or a synthetic peptide (usually from about 9 to about 25 amino acids in length) from a portion of rhesus MC-5R as disclosed in SEQ ID NO:2. Monospecific antibodies to rhesus MC-5R are purified from mammalian antisera containing antibodies reactive against rhesus MC-5R or are prepared as monoclonal antibodies reactive with rhesus MC-5R using the technique of Kohler and Milstein (1975, *Nature* 256: 495-497). Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for rhesus MC-5R. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with rhesus MC-5R, as described above. Rhesus MC-5R-specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of rhesus MC-5R protein or a synthetic peptide generated from a portion of rhesus MC-5R with or without an immune adjuvant.

Preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 μg and about 1000 μg of rhesus MC-5R protein associated with an acceptable immune adjuvant. Such acceptable adjuvants include, but are not limited to, Freund’s complete, Freund’s incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA. The initial immunization consists of rhesus MC-5R protein or peptide fragment thereof in, preferably, Freund’s complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster
injections are generally given an equal amount of rhesus MC-5R in Freund’s incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20°C.

Monoclonal antibodies (mAb) reactive with rhesus MC-5R are prepared by immunizing inbred mice, preferably Balb/c, with rhesus MC-5R protein. The mice are immunized by the IP or SC route with about 1 µg to about 100 µg, preferably about 10 µg, of rhesus MC-5R protein in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund’s complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 µg of rhesus MC-5R in a buffer solution such as phosphate buffered saline by the intravenous (IV) route.

Lymphocytes, from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco’s Modified Eagles Medium (DME) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using rhesus MC-5R as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press.

Monoclonal antibodies are produced in vivo by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 10^6 to about 6 x
$10^6$ hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.

*In vitro* production of anti-rhesus MC-5R mAb is carried out by growing the hybridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of rhesus MC-5R in body fluids or tissue and cell extracts.

It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce antibodies specific for rhesus MC-5R peptide fragments, or full-length rhesus MC-5R.

Rhesus MC-5R antibody affinity columns are made, for example, by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HCl (pH 8). The column is washed with water followed by 0.23 M glycine HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing full-length rhesus MC-5R or rhesus MC-5R protein fragments are slowly passed through the column. The column is then washed with phosphate buffered saline until the optical density ($A_{280}$) falls to background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6). The purified rhesus MC-5R protein is then dialyzed against phosphate buffered saline.

The DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of rhesus MC-5R. The recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of rhesus MC-5R. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further
comprise reagents such as recombinant MC-5R or anti-MC-5R antibodies suitable for detecting rhesus MC-5R. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

Pharmaceutically useful compositions comprising modulators of rhesus MC-5R may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington’s Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, modified rhesus MC-5R, or either MC-5R agonists or antagonists including tyrosine kinase activators or inhibitors.

Therapeutic or diagnostic compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders. The effective amount may vary according to a variety of factors such as the individual’s condition, weight, sex and age. Other factors include the mode of administration.

The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.

The term “chemical derivative” describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington’s Pharmaceutical Sciences.

Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents may be desirable.

The present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compounds can be administered in such oral
dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be administered at separately staggered times.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.

The following examples are provided to illustrate the present invention without, however, limiting the same hereto.

EXAMPLE 1
Isolation of the rhesus MC-5R gene
A rhesus (M. mulatta) genomic DNA library (Clontech) was screened with a random primed probe from human MC-5R (Yang et al., 1997, *Mol. Endocrinol* 11: 274-280), identifying one positive lambda phage clone. This clone was digested with EcoRI and BglII, analyzed by hybridization, and one positive fragment (1.6 kb) was subcloned into bluescript SKII (BS SKII). DNA sequencing revealed that EcoRI appears to cleave at a position immediately following the start codon, and BglII cleaves at a position down stream of the stop codon. DNA sequencing also revealed a PstI site 956 nucleotides down-stream of the EcoRI site. The phage clone was then digested with PstI which resulted in a 2 kb fragment that hybridized to the human MC-5R probe. The 2 kb PstI fragment was subcloned into bluescript SKII to determine the 5' untranscribed sequence, confirming that the original EcoRI-BglII fragment encodes the region from the 2nd amino acid to the stop codon. A sense primer, (5'-CTAGACTCGAGATGAAATCTCGTTCAC-3'; SEQ ID NO:3) and an antisense primer, (5'-CTCGAGGGATCCTAATCCCTCCGAGAAGCT-3'; SEQ ID NO:4) were used to amplify the open reading frame using the lambda phage clone as template. The 1.1 kb fragment encoding the full length rhesus MC-5R was cleaved with XhoI and BamHI and subcloned into pCDNA3.neo for expression studies. DNA sequencing confirmed that the sequence in the PCR fragment was identical to the previously determined sequence based on the 1.6 kb EcoRI-BglII fragment and 2 kb PstI fragments.

The deduced nucleotide and amino acid sequence of rhesus MC-5R are shown in Figure 1 (nucleotide sequence as set forth in SEQ ID NO:1) and Figure 2 (amino acid sequence as set forth in SEQ ID NO:2). The first Met residue in the sequence was deduced by determining the upstream nucleotide sequence and locating the presence of a stop codon upstream of the ATG codon. The rhesus MC-5R receptor protein does not have an unusually long N-terminal sequence as in mouse MC-5R (Fathi et al., 1995, *Neurochem. Res.* 20: 107-113). As with other melanocortin receptors, several features in rhMC-5R are shared with other melanocortin receptors and are absent in most other GPCR's of the rhodopsin subfamily (Fong et al, 1996, *Cell Signalling* 8: 217-224) including the EN motif in TM1, the lack of Cys in the loop between TM2 and TM3 or between TM4 and TM5, the Mxxxxxy motif in TM5, and the DPxxY motif in TM7. Since all melanocortin receptors lack Cys residues in the extracellular loops that are present in other
members of the rhodopsin sub-family, interhelical disulfide bond (e.g., between the Cys residues near the top of TM3 and TM5) may play the same function as interloop disulfide bond in most other GPCR’s.

EXAMPLE 2
Stable expression of rhesus MC-5R

The receptor plasmid was transfected into CHO dhfr- cells using lipofectamin (GIBCO). Transfected cells were selected by G418 for at least 2-3 weeks before binding and functional assays were performed. To determine the apparent binding affinity of peptides, transfected cells in 12-well plate were washed once with PBS and binding was done in HBSS with 25 mM Hepes, 0.5% NaN₃, 0.1% BSA, and protease inhibitor cocktail (4 ug/ml leupeptin, 40 ug/ml bacitracin, 5 ug/ml aprotinin, 10 uM phosphoramidon and 100 uM AEBSF). $^{125}$I-NDP-α-MSH (Amersham) at a concentration of 0.1 nM was used and non-specific binding was determined in the presence of 1 uM unlabeled NDP-α-MSH. After incubation at room temperature for 3 hours, wells were washed 3 times by PBS, lysed in 0.5 ml of 0.05% SDS and counted by a gamma counter. Alternatively, the same results were obtained using cell suspensions followed by GF/C filter filtration (Huang, et al., 1994, Biochemistry 33: 3007-3013).

To determine the functional activation of receptors, stably transfected CHO cells were washed once with PBS without Ca$^{2+}$/Mg$^{2+}$, dissociated by non-enzymatic dissociation medium (Specialty Media, Inc.) at 37°C for 10 min. Dissociated cells were resuspended in EBSS buffer containing 25 mM Hepes, 5 mM MgCl₂, 0.1% BSA and 50 mM IBMX and incubated with agonist at room temperature for 45 min. The agonist activation was terminated by boiling for 4 min. Intracellular cyclic AMP concentration was measured by the Amersham SPA assay system (Huang, et al., 1997, J. Receptor Signal Transduc. Res. 17:599-607).

Human MC-5R and MC-5R genomic DNA were obtained from Dr. Ira Gantz (Gantz et al., 1993, J. Biol. Chem. 268: 8246-8250) and subcloned into the pIRESneo expression vector, and stably transfected into CHO cells. Single clones were used in all pharmacological studies as described above.

EXAMPLE 3

- 32 -
Pharmacological Properties of Rhesus MC-5R

A cDNA encoding human MC-5R subcloned into the pIRES1neo expression vector (Clontech) and stably transfected into CHO cells was used as a reference for the pharmacological properties of the rhesus MC-5R. Single clones were used in all pharmacological studies as described above. The functional properties of rhMC-5R were determined by heterologous expression in CHO cells. Mock transfected CHO cells did not exhibit any binding of \(^{125}\text{I}\)NDP-\(\alpha\)-MSH or any cAMP response to \(\alpha\)-MSH.

The rhesus MC-5R was functionally characterized in CHO cells (Figure 3A and 3B). In contrast to the lack of agonist activity of Shu-9119 at MC-5R, Shu-9119 is an agonist for MC-5R. In addition, all tested peptides are full agonist for the rhesus MC-5R while \(\gamma\)2-MSH and MT-II are partial agonists for the human MC-5R. As shown in Table 1, many peptides exhibit a higher binding affinity or activation potency at the rhesus MC-5R than at the human MC-5R.

The rhesus MC-5R gene was isolated and purified and the concomitant receptor was functionally characterized in a heterologous expression system. Shu-9119 is shown to be an agonist for both the rhesus and human MC-5R. The pharmacological properties of rhesus MC-5R are significantly different from those of the human MC-5R. Especially when the receptor activation is measured, 5 of the 6 tested peptides are significantly more potent at the rhesus MC-5R than at the human MC-5R. Species-dependent pharmacological property has been reported (e.g. Fong et al., 1992, *J. Biol. Chem.* 267: 25668-25671; Oksenberg, et al., 1992, *Nature* 360: 161-163), apparently due to a small number of phylogenetically divergent residues in the transmembrane region. Unlike the NK1 receptor or 5HT1b receptor in which the rank order of potency can be reversed between two species homologs, the human and rhesus MC-5R maintain the same rank order of potency for all tested agonists (Figure 4). The systematic difference in the absolute potency between human and rhesus MC-5R is consistent with the interpretation that the strength of interaction (or intermolecular distance) rather than the mode of interaction is different between human and rhesus MC-5R. Additionally, the potency of \(\alpha\)-MSH and \(\gamma\)2-MSH for the mouse MC-5R (Labbe et al., 1994, *Biochemistry* 33: 4513-4549) are more similar to those of rhesus MC-5R and less similar to those of human MC-5R (Figure 4). Such a pattern would predict that those transmembrane residues that are common in mouse
and rhesus MC-5R but different in human MC-5R may determine the observed species difference.

Table 1

<table>
<thead>
<tr>
<th>Ligands</th>
<th>IC50, nM</th>
<th>EC50, nM</th>
<th>Maximal response (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rhMC-5R</td>
<td>hMC-5R</td>
<td>rhMC-5R</td>
</tr>
<tr>
<td>NDP</td>
<td>0.2±0.1(2)</td>
<td>0.5±0.1(6)</td>
<td>0.02±0.01(3)</td>
</tr>
<tr>
<td>α-MSH</td>
<td>14±1(2)</td>
<td>1800±200(4)</td>
<td>0.2±0.1(3)</td>
</tr>
<tr>
<td>γ2-MSH</td>
<td>1700±200(2)</td>
<td>9700±2900(2)</td>
<td>17±3(3)</td>
</tr>
<tr>
<td>MTII</td>
<td>5±0.2(3)</td>
<td>18±3(4)</td>
<td>0.02±0.01(3)</td>
</tr>
<tr>
<td>Shu9119</td>
<td>0.02±0.001(3)</td>
<td>0.4±0.2(4)</td>
<td>0.007±0.005(2)</td>
</tr>
<tr>
<td>ACTH1-24</td>
<td>15±1(2)</td>
<td>1050±500(3)</td>
<td>0.2±0.1(3)</td>
</tr>
</tbody>
</table>

Table 1 shows that although α-MSH exhibits a very low apparent binding affinity for the human MC-5R, its activation potency (EC50=12 nM) is much higher. In some brain regions, the α-MSH concentration can reach 4 to 54 pmol/g, which is consistent with the notion that α-MSH can be an endogenous agonist for the human MC-5R. The observation that IC50 values are larger than EC50 values actually applies to many MC-5R agonists (Figure 4). Based on modeling prediction, activation potency will be smaller than the intrinsic agonist binding affinity when the receptor-G protein binding affinity is sufficiently high (Kenakin et al., 1989, Mol. Pharmacol. 35: 214-222), thus implying that MC-5R couples to G proteins tightly.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.
WHAT IS CLAIMED:

1. A purified nucleic acid molecule encoding a rhesus melanocortin 5 receptor protein which comprises the nucleotide sequence

GCTGTCCTTC TTGTGTTAACC TTCTCGGATT GTGAAATTAA AATGTGTTTT ACGTAGAATTT
TGCTGCCAAG ACAAGAGGTT AATTCTTCCA GCAATGAATT CCTCGTTTCA CCTGACATTTC
TTGGATCTCA ACCTGATGC CACAGAGGCG AACCTTTCAG GACCCGAGGT CAGAAAAAG
TCTCTGCCCT GTGAAAACAT GGGCATGGCT GTGGAGGTTGT TTCTCACCTCT GGGTGGCCATC
AGCCTCGTGG AGGACATCATG GGTATTAGGC GCCATAGTG AGAACAAGAA CCTCCGACTGC

15 CCAATGTACT TCTTCTGATG CAGCCTGCGG GTGGCCGCACA TGCTGCTGAG CATGTACCAAC
GCTTGGGAGA CCATTCCCAAT CTACCTGCTTC ACCAACAAACG ACCCTTCGAT ACCAGACGCC
TTTGGGGGG ACATGGCAAA GTGGTTTGGAC TCCATGATCT GCAATTCGGT GGTGGGCTCC
ATGTGCGACT GTGCTGCGCAT TGGGCTGAGT AGGTACGTCGA CGGCTTCTTA TGCCCTGCGG
TACCCACACA CTAGACGCGG GAGCCGCTCAG GGCGCATTCA TGCCCGCTGCT GTGCTGCTTC

20 TGACCCGGGT GCACGGCTGT GTTCTATCTGG TACCTCCAGT CACCTACTGG CATTCTCTGGC
CTCATCTCCA TTCTTCGATC AGATGCTCTTC CTTCTTCGAT GTCTGATCAT ACACATTGTC
CTCTCGGCCG GAATCTAGGC CAGCGGATGT CCAGCGCTGGT CCAGCGCCAG CTTCTGGCGG
CAGAGACCA GGTGCGAGGG CGCGCTACCC CTGACCAGTG TTGGCTGCTG TGCTGCTGCTG
TGCTGCTGC GCTTCTGGTG GCAATCTCAG TTAATGCTTT TTGCGGTCTA CAACCTCTAC

25 A purified DNA molecule encoding rhesus melanocortin 5 receptor protein wherein said DNA molecule encodes a protein consisting essentially of the amino acid sequence

M Y F F V C S L A V A D M L V S M S N A W E T T I Y L L N N K H L V
I A D A F V R H I D N V P D S M I C I S V V A S M C S L L A I A V D R
Y V T V F Y A L R Y H H I M T A R R S G A I I A G I W A F C T G C G I
V F I L Y S E S T Y V I L C L I S M F F T M L F L L V C L Y I H M F L
L A R T H A K R M A A L P G A S S A R Q R T S V Q G A V T L T M L L G

- 35 -
3. An expression vector for the expression of a rhesus MC-5R protein in a recombinant host cell wherein said expression vector comprises a DNA molecule which encodes the amino acid sequence of claim 2.

4. An expression vector of claim 3 which is a eukaryotic expression vector.

5. An expression vector of claim 3 which is a prokaryotic expression vector.

6. A host cell which expresses a recombinant rhesus MC-5R protein wherein said host cell contains the expression vector of claim 3.

7. A host cell which expresses a recombinant rhesus MC-5R protein wherein said host cell contains the expression vector of claim 4.

8. A host cell which expresses a recombinant rhesus MC-5R protein wherein said host cell contains the expression vector of claim 5.

9. A host cell of claim 6 wherein said rhesus MC-5R protein is overexpressed from said expression vector.

10. A host cell of claim 7 wherein said rhesus MC-5R protein is overexpressed from said expression vector.

11. A host cell of claim 8 wherein said rhesus MC-5R protein is overexpressed from said expression vector.

12. A subcellular membrane fraction obtained from the host cell of claim 9 which contains recombinant rhesus MC-5R protein.
13. A subcellular membrane fraction obtained from the host cell of claim 10 which contains recombinant rhesus MC-5R protein.

14. A subcellular membrane fraction obtained from the host cell of claim 11 which contains recombinant rhesus MC-5R protein.

15. A purified DNA molecule which consists of the nucleotide sequence

\[
\begin{align*}
10 \text{ GCTTCTTCG} & \quad \text{TGTTGTAACC} & \quad \text{TCTCTGGATT} & \quad \text{GTGAATTTAA} & \quad \text{AATGTGTTTTT} & \quad \text{ACAGTAAATT} \\
& \quad \text{TGCTGCCAAG} & \quad \text{ACAAAGGCTG} & \quad \text{AATTTCTCCA} & \quad \text{GCAATGAAAT} & \quad \text{CCCTGTTCCA} & \quad \text{CTTGGCATTTT} \\
& \quad \text{TTGGATCCTCA} & \quad \text{ACCTGAATGC} & \quad \text{CACAGAGGCG} & \quad \text{AACCTTTCAG} & \quad \text{GACCCGATGT} & \quad \text{CAGAAACAAG} \\
& \quad \text{TCTTCGCCCT} & \quad \text{GTGAACACAT} & \quad \text{GGCGATGCGT} & \quad \text{GTGGGAGGTGT} & \quad \text{TTTCATCTCT} & \quad \text{GGTGGCCATC} \\
& \quad \text{AGCTCGTGCG} & \quad \text{AGAACATCTT} & \quad \text{GGTTATAGGG} & \quad \text{GCCCAGTGAG} & \quad \text{AGAAACAAATA} & \quad \text{CTTGGCATTGC} \\
15 \text{ CCCATGTACT} & \quad \text{TCTTGCTATG} & \quad \text{CAGGCGTGGGC} & \quad \text{GTGGCGGCGA} & \quad \text{TGTGCGTAC} & \quad \text{CTGTCGCAAC} \\
& \quad \text{GGCTGGGAGA} & \quad \text{CCACCATCCT} & \quad \text{CTACCTGCTC} & \quad \text{ACAACAAGG} & \quad \text{ACCTAGTGAT} & \quad \text{AGGACAGGCC} \\
& \quad \text{TCTGTGGCGC} & \quad \text{ACATGGACAA} & \quad \text{CGTGGTTGAC} & \quad \text{TCCATGATCT} & \quad \text{GCAATTCGCGT} & \quad \text{GGTGCGGCTC} \\
& \quad \text{GTGTACAGCT} & \quad \text{TGGTGGCAGT} & \quad \text{AGTACGCTA} & \quad \text{CCTCTTCTCA} & \quad \text{TGGCCGTCGC} & \quad \text{TACCCACACA} \\
& \quad \text{TCATGACGGC} & \quad \text{GAGGCGCTCG} & \quad \text{GGCGCCATCA} & \quad \text{TGGCGGCGCAT} & \quad \text{TGGGCTTTC} & \quad \text{TGCACCGGCG} \\
20 \text{ CGGCGATGCT} & \quad \text{CCTTCACTGCT} & \quad \text{TACCTGCTGC} & \quad \text{CCACCTAGCT} & \quad \text{CATCCTGCTGC} \\
& \quad \text{CTCATCTCCA} & \quad \text{TCTCTTCTCAC} & \quad \text{GATGCTCTTCC} & \quad \text{CTCTGCGTGT} & \quad \text{GTCTGTACAT} & \quad \text{ACACATGTTC} \\
& \quad \text{CTCTGGGGC} & \quad \text{GGAATCGACG} & \quad \text{CAGGGCGATG} & \quad \text{GCCGGCTCCTC} & \quad \text{GGCCGGCCG} & \quad \text{TCTCTGCGC} \\
& \quad \text{CAGAGGAACCA} & \quad \text{CUGTGAAGGG} & \quad \text{CGGGCGTACC} & \quad \text{CTACCAATGC} & \quad \text{TGGTGGCCGT} & \quad \text{GTGTCGCGG} \\
& \quad \text{TGCTGGGGCGC} & \quad \text{CGTTCTTTCTC} & \quad \text{GCACCTCTATT} & \quad \text{TGAATGCTTT} & \quad \text{TGGCCCTCCA} & \quad \text{GAACCTCTAC} \\
25 \text{ TSCTCTTCCGT} & \quad \text{TCACTTGCTCA} & \quad \text{CTTCAATATG} & \quad \text{TACCCTCTCC} & \quad \text{TCATCATGTT} & \quad \text{TACCTGCGT} \\
& \quad \text{GTGGACCCTTC} & \quad \text{TCTATATGGC} & \quad \text{TTCCGGCGACG} & \quad \text{CGGGGACAGC} & \quad \text{CAGAAGCGTT} & \quad \text{TACCTCGATTT} \\
& \quad \text{ATGCTGCGCC} & \quad \text{GAGGCTTCCG} & \quad \text{AATCGCCTGCG} & \quad \text{AGTCGTCGCC} & \quad \text{GAAGGGATTAA} & \quad \text{AGTACGAAAGT} \\
(\text{SEQ ID NO:1}).
\end{align*}
\]

16. A purified nucleic acid molecule encoding a rhesus melanocortin 5 receptor protein which consists of the amino acid sequence

\[
\begin{align*}
\text{MNSSFHLHFLDLNLNATENEGLNSGPRKNSPSKSCPEN} \\
\text{MGMAVEVFVTLGLAISLVLENVILVIGAIKKNKNLHCP} \\
\text{MYFVCSVLSLAVADMMLSMSNNAWETITIYLLNKNKHLV}
\end{align*}
\]

17. The purified DNA molecule of claim 15 which consists of a nucleotide sequence from nucleotide 94 to nucleotide 1068 of SEQ ID NO:1.

18. An expression vector for the expression of a rhesus MC-5R protein in a recombinant host cell wherein said expression vector comprises a DNA molecule of claim 17.

19. An expression vector of claim 18 which is a eukaryotic expression vector.

20. An expression vector of claim 18 which is a prokaryotic expression vector.

21. A host cell which expresses a recombinant rhesus MC-5R protein wherein said host cell contains the expression vector of claim 19.

22. A host cell which expresses a recombinant rhesus MC-5R protein wherein said host cell contains the expression vector of claim 20.

23. A host cell which expresses a recombinant rhesus MC-5R protein wherein said host cell contains the expression vector of claim 21.

24. A subcellular membrane fraction obtained from the host cell of claim 22 which contains recombinant rhesus MC-5R protein.
25. A subcellular membrane fraction obtained from the host cell of claim 23 which contains recombinant rhesus MC-5R protein.

26. A process for the expression of a rhesus MC-5R protein in a recombinant host cell, comprising:
   (a) transfecting the expression vector of claim 3 into a suitable host cell; and,
   (b) culturing the host cells of step (a) under conditions which allow expression of the rhesus MC-5R protein from the expression vector.

27. A purified rhesus melanocortin 5 receptor protein which comprises the amino acid sequence as follows:

```
M Y F F V C S L A V A D M L V S M S N A W E T I T I Y L L N N K H L V
I A D A F V R H I D N V F D S M I C I S V V A S M C S L L A I A V D R
Y V T V F A R L R Y H H I M T A R R S G A I I A G I W A F C T G C G I
V F I L Y S E S T Y V I L C L I S M F F T M L F L L V C L Y I H M F L
L A R T A K R M A A L P G A S S A R Q R T S V Q G A V T L T M L L G
V F I V C W A P F F L H L I L M L S C P Q N L Y C S C F M S H P N M Y
L I L I M C S V V D P L I Y A F R S R E M R K T F K E I I C C R G F
R I A C S C P G R D, which comprises the amino acid sequence as set forth in a three-letter abbreviation in SEQ ID NO:2.
```

28. A purified rhesus melanocortin 5 receptor protein which consists of the amino acid sequence as set forth in SEQ ID NO:2.

29. A method for determining whether a substance is capable of binding to rhMC-5R comprising:
   (a) providing test cells by transfecting cells with an expression vector that directs the expression of rhMC-5R in the cells;
   (b) exposing the test cells to the substance;
   (c) measuring the amount of binding of the substance to rhMC-5R;
(d) comparing the amount of binding of the substance to rhMC-5R in the test cells with the amount of binding of the substance to control cells that have not been transfected with rhMC-5R.

30. A method for determining whether a substance is capable of activating rhMC-5R comprising:
   (a) providing test cells by transfecting cells with an expression vector that directs the expression of rhMC-5R in the cells;
   (b) exposing the test cells to the substance;
   (c) measuring the amount of accumulated intracellular cAMP;
   (d) comparing the amount of cAMP in the test cells in response to the substance with the amount of cAMP in test cells that have not been exposed to the substance.

31. A method of identifying a substance which modulates MC-5R receptor activity, comprising:
   (a) combining a test substance in the presence and absence of a MC-5R receptor protein wherein said MC-5R receptor protein comprises the amino acid sequence as set forth in SEQ ID NO:2; and,
   (b) measuring and comparing the effect of the test substance in the presence and absence of the MC-5R receptor protein.

32. A method for determining whether a substance is a potential agonist or antagonist of MC-5R comprising:
   (a) transfecting or transforming cells with an expression vector of claim 3 that directs expression of MC-5R in the cells, resulting in test cells;
   (b) allowing the test cells to grow for a time sufficient to allow MC-5R to be expressed;
   (c) exposing the cells to a labeled ligand of MC-5R in the presence and in the absence of the substance;
   (d) measuring the binding of the labeled ligand to MC-5R; where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then the substance is a potential agonist or antagonist of MC-5R.
33. A method for determining whether a substance is capable of binding to MC-5R comprising:
   (a) transfecting or transforming cells with an expression vector of claim 3 that directs the expression of MC-5R in the cells, resulting in test cells;
   (b) exposing the test cells to the substance;
   (c) measuring the amount of binding of the substance to MC-5R;
   (d) comparing the amount of binding of the substance to MC-5R in the test cells with the amount of binding of the substance to control cells that have not been transfected with MC-5R;
   wherein if the amount of binding of the substance is greater in the test cells as compared to the control cells, the substance is capable of binding to MC-5R.

34. A method for determining whether a substance is capable of binding to MC-5R comprising:
   (a) transfecting or transforming cells with an expression vector of claim 3 that directs the expression of MC-5R in the cells, resulting in test cells;
   (b) preparing membranes containing MC-5R from the test cells and exposing the membranes to a ligand of MC-5R under conditions such that the ligand binds to the MC-5R in the membranes;
   (c) subsequently or concurrently to step (b), exposing the membranes from the test cells to a substance;
   (d) measuring the amount of binding of the ligand to the MC-5R in the membranes in the presence and the absence of the substance;
   (e) comparing the amount of binding of the ligand to MC-5R in the membranes in the presence and the absence of the substance where a decrease in the amount of binding of the ligand to MC-5R in the membranes in the presence of the substance indicates that the substance is capable of binding to MC-5R.

35. A method for determining whether a substance is capable of binding to MC-5R comprising:
   (a) transfecting or transforming cells with an expression vector of claim 3 that directs the expression of MC-5R in the cells, resulting in test cells;
(b) preparing membranes containing MC-5R from the test cells and exposing the membranes from the test cells to the substance;
(c) measuring the amount of binding of the substance to the MC-5R in the membranes from the test cells;
(d) comparing the amount of binding of the substance to MC-5R in the membranes from the test cells with the amount of binding of the substance to membranes from control cells that have not been transfected with MC-5R, where if the amount of binding of the substance to MC-5R in the membranes from the test cells is greater than the amount of binding of the substance to the membranes from the control cells, then the substance is capable of binding to MC-5R.

36. A method of identifying agonists of MC-5R comprising:
(a) transfecting or transforming cells with a first expression vector of claim 3 which directs expression of MC-5R and a second expression vector which directs the expression of a promiscuous G-protein, resulting in test cells;
(b) exposing the test cells to a substance that is a suspected agonist of MC-5R;
(c) measuring the level of inositol phosphates in the cells; where an increase in the level of inositol phosphates in the cells as compared to the level of inositol phosphates in the cells in the absence of the suspected agonist indicates that the substance is an agonist of MC-5R.

37. A method of identifying antagonists of MC-5R comprising:
(a) transfecting or transforming cells with a first expression vector of claim 3 which directs expression of MC-5R and a second expression vector which directs the expression of a promiscuous G-protein, resulting in test cells;
(b) exposing the test cells to a substance that is an agonist of MC-5R;
(c) subsequently or concurrently to step (b), exposing the test cells to a substance that is a suspected antagonist of MC-5R;
(d) measuring the level of inositol phosphates in the cells; where a decrease in the level of inositol phosphates in the cells in the presence of the suspected antagonist as compared to the level of inositol phosphates in the cells in the
absence of the suspected antagonist indicates that the substance is an antagonist of MC-5R.

38. A method of identifying antagonists of MC-5R as recited in claim 37 wherein the first and second expression vectors of step (a) are replaced with a single expression vector which expresses a chimeric MC-5R protein fused at its C-terminus to a promiscuous G-protein.

39. An antibody that binds specifically to MC-5R protein wherein the MC-5R receptor protein comprises the amino acid sequence as set forth in SEQ ID NO:2.
GCTGTCTTTTCTTTG

GTAACCTCTCTGGATATTGTGAATTTAAATGTTTTTACAGTAAATTGGCTGCAAGACAAAGAGAGTAGA
ATT TCT CCA GCA ATG AAT TCC TCG TTT CAC CTG CAT TTC TTG GAT CTC AAC
CTG AAT GCC ACA GAG GGC AAC CTT TCA GGA CCC AGT GTC AGA AAC AAG TCT
TCG CCC TGT GAA AAC ATG GGC ATG GCT GTG GAG GTG TTT CTC ACT CTG GGT
GCC ATC AGC CTC GTG GAG AAC ATC TTG GTT ATA GGG GCC ATA GTG AAG AAC
AAA AAC CTG CAC TGC CCC ATG TAC TTC TTC GTA TGC AGC CTG GCG GTG GCC
GAC ATG CTG GTG AGC ATG TCC AAC GCC TGG GAG ACC ATC ACC ATC TAC CTG
CTC AAC AAC AAG CAC CTA GTG ATA GCA GAC GCC TTT GTG CGC CAC ATT GAC
AAC GTG TTT GAC TCC ATG ATC TGC ATT TTC GTG GTG GCC ATG TGC AGC
TTG CTG GCC ATT GCG GTG GAT AGG TAC GTC ACC GTG TCC TAT GCC CTG CGC
TAC CAC CAC ATC ATG ACG GCG AGG CGC TCG GGG GCC ATC ATC GCC GCC GGC ATC
TGG GCT TTC TGC ACC GGG TGC GCC ATC GTC TTC ATC CTG TAC TCC GAG TCC
ACC TAC GTC ATC CTG TGC CTC ATC TCC ATG TTT TTC ATC AGC ATG CTC TTC CTC
CTG GTG TGT CTG TAC ATA CAC ATG TTC CTC CTG GCG CGG ACT CAC GCC AAG
CGG ATG GCG GCT CTG CCC GGG GCC AGC TCT GCG CGG CAG AGG ACC AGC GTG
CAG GCC GGC GTC ACC CTC ACC ATG CTG CTG GCC GTG TCC ATC GTG TGG TGG
GCC CCG TTC TTC CTG CAT CTC ATT TTA ATG CCT TCT TGC CCT CAG AAC CTC
TAC TGC TCT TGC TTC ATG TCT CAC TTC AAT ATG TAC CTC ATC TCT ATC ATG
TGT AAC TCC GTG GTG GAC CCT CTC ATA TAT GCC TCC CGC AGC CGG GAG ATG
CGC AAG AGC TTT AAG GAG ATT ATT TGC TGC CGA GCC TTC CGA ATC GCC TGC
AGC TGT CCC GGA AGG GAT TAA GGTACAAAGT (SEQ ID NO:1)

FIG. 1
Met Asn Ser Ser Phe His Leu His Phe Leu Asp Leu Asn Leu Asn
7 ATG AAT TCC TCG TTT CAC CTG CAT TTC TTG GAT CTC AAC CTG AAT

Ala Thr Glu Gly Asn Leu Ser Gly Pro Ser Val Arg Asn Lys Ser Ser Pro
52 GCC ACA GAG GGC AAC CTT TCA GGA CCC AGT GTC AGA AAC AAG TCT TCG CCC

Cys Glu Asn Met Gly Met Ala Val Glu Val Phe Leu Thr Leu Gly Ala Ile
103 TGT GAA AAC ATG GGC ATG GCT GTG GAG GTG TTT CTC ACT CTG GGT GCC ATC

Ser Leu Val Glu Asn Ile Leu Val Ile Gly Ala Ile Val Lys Asn Asn
154 AGC CTC GTG GAG AAC ATC TTG GTT ATA GGG GCC ATA GTG AAG AAC AAA AAC

Leu His Cys Pro Met Tyr Phe Phe Val Cys Ser Leu Ala Val Ala Asp Met
205 CTG CAC TGC CCC ATG TAC TTC TTC GTA TGC AGC CTG GCG GTG GCC GAC ATG

Leu Val Ser Met Ser Asn Ala Trp Glu Thr Ile Thr Ile Tyr Leu Leu Asn
256 CTG GTG AGC ATG TTC AAG GCC TTC GGA GAG ACC ATC ACC ATC TAC CTG CTC AAC

Asn Lys His Leu Val Ile Ala Asp Ala Phe Val Arg His Ile Asp Asn Val
307 AAC AAG CAC CTA GTG ATA GCA GAC GCC TTT GTG CGC CAC ATT GAC AAC GTG

Phe Asp Ser Met Ile Cys Ile Ser Val Val Ala Ser Met Cys Ser Leu Leu
358 TTT GAC TCC ATG ATC TGC ATT TCC GTG GTG GCG TCC ATG TGC AGC TTG CTG

Ala Ile Ala Val Asp Arg Tyr Val Thr Val Phe Tyr Ala Leu Arg Tyr His
409 GCC ATT GCG GTG GAT AGG TAC GTC ACC GTC TTC TAT GCC CTG CGC TAC CAC

His Ile Met Thr Ala Arg Arg Ser Gly Ala Ile Ile Ala Gly Ile Trp Ala
460 CAC ATC ATG ACG GCG AGG CGC TCG GGG GCC ATC ATC GCC GCC ATC TGG GTT

Phe Cys Thr Gly Cys Gly Ile Val Phe Ile Leu Tyr Ser Glu Ser Thr Tyr
511 TTC TGC ACC GGG TGC GCC ATC GTC TTC ATC CTG TAC TCC GAG TCC ACC TAC

Val Ile Leu Cys Leu Ile Ser Met Phe Phe Thr Met Leu Phe Leu Leu Val
562 GTC ATC CTG TGC CTC ATC TCC ATG TTC TTC ACG ATG CTC TTC CTG CTC GTG

Cys Leu Tyr Ile His Met Phe Leu Leu Ala Arg Thr His Ala Lys Arg Met
613 TGT CTG TAC ATA CAC ATG TTC CTG ATG CGG CGG ACT CAC GCC AAG CGG ATG

Ala Ala Leu Pro Gly Ala Ser Ser Ala Arg Gln Arg Thr Ser Val Glu Gln Gly
664 GCG GCT CTG CCC GGG GCC AGC TCT GCG CGG CAG AGC GTG CAG GCC

FIG. 2A
Ala Val Thr Leu Thr Met Leu Leu Gly Val Phe Ile Val Cys Trp Ala Pro
715 GCG GTC ACC CTC ACC ATG CTG CTG GGC GTG TTC ATC GTG TGC TGG GCC CCG
Phe Phe Leu His Leu Ile Leu Met Leu Ser Cys Pro Gln Asn Leu Tyr Cys
766 TTC TTC CTG CAT CTC ATT TTA ATG CTT TCT TGC CCT CAG AAC CTC TAC TGC
Ser Cys Phe Met Ser His Phe Asn Met Tyr Leu Ile Leu Ile Met Cys Asn
817 TCT TGC TTC ATG TCT CAC TTC AAT ATG TAC CTC ATC ATC ATG TGT AAC
Ser Val Val Asp Pro Leu Ile Tyr Ala Phe Arg Ser Arg Glu Met Arg Lys
868 TCC GTG GTG GAC CCT CTC ATA TAT GCC TTC CGC AGC CGG GAG ATG CGC AAG
Thr Phe Lys Glu Ile Ile Cys Arg Gly Phe Arg Ile Ala Cys Ser Cys
919 ACG TTT AAG GAG ATT ATT TGC TGC CGA GGC TTC CGA ATC GCC TGC AGC TGT
Pro Gly Arg Asp (SEQ ID NO:2)
970 CCC GGA AGG GAT TAA (COMPRISED WITHIN SEQ ID NO:1)

FIG.2B
**FIG. 3A**

![Graph showing binding of 125I-NDP-α-MSH, γ2-MSH, and SHU9119 to rhMC5R.](image)

**FIG. 3B**

![Graph showing cAMP production in response to NDP-α-MSH, γ2-MSH, and SHU9119.](image)
SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> DNA MOLECULES ENCODING THE MELANOCORTIN 5 RECEPTOR PROTEIN FROM RHESUS MONKEY

<130> 20191 PCT

<150> 60/107,632

<151> 1998-11-09

<160> 4

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1080

<212> DNA

<213> rhesus monkey (Macaca mulatta)

<400> 1

gctgtcttttc tttggttaacc tctctggatt gtgaatattaa aatgtttttt acagtaaat 60
tgctgcacagg acaagaggtt aatattttca gcaatgaatt cctgttttca cctgcatttc 120
ttgatcttca aacctgaatgc cacagagggc aaccttcccag gacccagttg cagaaacaaag 180
tcttcgccttc ggcacagcat gttgagttgt ttctgtactt ctgctgtacg cgtgctgcctc 240
gagcttgtgg agaacaacatc gtttataggg gccatagtgga gaagacaaaaa cctgccactgc 300
ccctcgactct ctctcttgatc cagcctgccc ggtgcgcaca gctgctgtagc catgctccaac 360
gccctggaga cccatcaacctat ctacctgctc aacaacaagc acctagtgat acagagaacc 420
tttctgcgca acatgacaga cgtgggtgac tccatgactct gcatttccgt ggtgctgccg 480
atgtgcagct tgcctggccat tgcggttgtag aggtacgcta cggctttctca tgcctctgctc 540
taccacacca tcatgaaggc gagggcttcg ggggccccaa tcgccccgca tggccccctc 600
tgcacccgctt ggcagcatgt tccatcctct taeccgagtt cacaactactg catctctgct 660
tccatcttcca tgtctcttcac gatgtccttc ctctggcttg tgcctatcat acacatgctc 720
tctctgcccag gcaccagagc cacaggttag ggcgcctctgc cgggccccag cctgggaggg 780
cagagacca gcgtgcaggg ggcgtgcatcc atcaccctgc tgggggctgc gttcactgct 840
tgctgcatgg gcgtctctccct gcacacctct ttatgtcttt cttgcacccgta qaactcttac 900
tgctctttcg tcatatgtgg ttcctcctctc ttcctacatg tcacatgtga taactcccttg 960
tggccacccgc tcatatatgc tccctgcagc tgggaggttc gcaagacgtg taaggagatt 1020
atgtgcctgc gaggctcttccg aatgcgcctgc agctgtcccag gaagggatta agtacaaagt 1080

<210> 2

<211> 325

<212> PRT

<213> rhesus monkey (Macaca mulatta)

<400> 2

Met Asn Ser Ser Phe His Leu His Phe Leu Asp Leu Asn Leu Asn Ala
1      5      10      15
Thr Glu Gly Asn Leu Ser Gly Pro Ser Val Arg Asn Lys Ser Ser Pro
20     25     30
Cys Glu Asn Met Gly Met Ala Val Glu Val Phe Leu Thr Leu Gly Ala
35     40     45

-1-
Ile Ser Leu Val Glu Asn Ile Leu Val Ile Gly Ala Ile Val Lys Asn  
50  55  60
Lys Asn Leu His Cys Pro Met Tyr Phe Phe Val Cys Ser Leu Ala Val  
65  70  75  80
Ala Asp Met Leu Val Ser Met Ser Asn Ala Trp Glu Thr Ile Thr Ile  
85  90  95
Tyr Leu Leu Asn Asn Lys His Leu Val Ile Ala Asp Ala Phe Val Arg  
100 105 110
His Ile Asp Asn Val Phe Asp Ser Met Ile Cys Ile Ser Val Val Ala  
115 120 125
Ser Met Cys Ser Leu Leu Ala Ala Val Asp Arg Tyr Val Thr Val  
130 135 140
Phe Tyr Ala Leu Arg Tyr His His Ile Met Thr Ala Arg Arg Ser Gly  
145 150 155 160
Ala Ile Ile Gly Ile Trp Ala Phe Cys Thr Gly Cys Gly Ile Val  
165 170 175
Phe Ile Leu Tyr Ser Glu Ser Thr Tyr Val Ile Leu Cys Leu Ile Ser  
180 185 190
Met Phe Phe Thr Met Leu Phe Leu Leu Val Cys Leu Tyr Ile His Met  
195 200 205
Phe Leu Leu Ala Arg Thr His Ala Lys Arg Met Ala Ala Leu Pro Gly  
210 215 220
Ala Ser Ser Ala Arg Gln Arg Thr Ser Val Gln Gly Ala Val Thr Leu  
225 230 235 240
Thr Met Leu Leu Gly Val Phe Ile Val Cys Trp Ala Pro Phe Phe Leu  
245 250 255
His Leu Ile Leu Met Leu Ser Cys Pro Gln Asn Leu Tyr Cys Ser Cys  
260 265 270
Phe Met Ser His Phe Asn Met Tyr Leu Leu Ile Leu Ile Met Cys Asn Ser  
275 280 285
Val Val Asp Pro Leu Ile Tyr Ala Phe Arg Ser Arg Glu Met Arg Lys  
290 295 300
Thr Phe Lys Glu Ile Ile Cys Cys Arg Gly Phe Arg Ile Ala Cys Ser  
305 310 315 320
Cys Pro Gly Arg Asp  
325

<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> OLIGONUCLEOTIDE

<400> 3
cctagacgctg aagatgacttc ctcgtttcaca

<210> 4
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> OLIGONUCLEOTIDE
ctcgagggat ccttaatccc ttccgggaca gct

33
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6): C12N 5/10, 5/12, 15/63, 15/64; C07K 14/705, 14/71, 14/72


According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, CAS ONLINE, MEDLINE, BIOSIS, EMBASE, CAPLUS

search terms: nucleic acid, DNA, polynucleotide, rhesus melanocortin 5 receptor, recombinant, isolation, production.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 5,710,265 A (YAMADA ET AL) 20 January 1998 (20/01/98), see entire document.</td>
<td>1-28</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

| * | Special categories of cited documents: |
| **| document defining the general state of the art which is not considered to be of particular relevance |
| *A* | earlier document published on or after the international filing date |
| *B* | document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) |
| *L* | document referring to an oral disclosure, use, exhibition or other means |
| *O* | document published prior to the international filing date but later than the priority date claimed |

**Date of the actual completion of the international search**

14 JANUARY 2000

**Date of mailing of the international search report**

16 FEB 2000

Name and mailing address of the ISA/US Commission of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer: PREMA MERTZ

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Form PCT/ISA/210 (continuation of second sheet)(July 1992)
INTernational Search Report

Box 1 Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box 2 Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

   Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☑ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. 1-28

Remark on Protest
☐ The additional search fees were accompanied by the applicant’s protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER:

US CL:

536/23.1, 23.5; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1; 530/350

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-28, drawn to a nucleic acid molecule encoding a rhesus melanocortin 5 receptor protein, an expression vector, a host cell, a process for the expression of a rhesus MC-5R protein in a recombinant host cell, and a purified rhesus melanocortin 5 receptor protein.

Group II, claims 29-38, drawn to a method for determining whether a substance is capable of binding to rhMC-5R.

Group III, claim 39, drawn to an antibody that binds specifically to MC-5R protein.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, a nucleic acid molecule encoding a rhesus melanocortin 5 receptor protein, an expression vector, a host cell, a process for the expression of a rhesus MC-5R protein in a recombinant host cell, and a purified rhesus melanocortin 5 receptor protein. Further pursuant to 37C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.